Abstract: Cannabis as a Gateway Drug for Opioid Use Disorder
Emerging evidence suggests that adolescent cannabis use may biologically and behaviourally increase vulnerability to later opioid use and the development of opioid use disorder (OUD). The paper argues that while shared risk factors—such as trauma, impulsivity, psychiatric symptoms, and genetic predisposition—contribute to both cannabis and opioid use, cannabis itself may introduce additional risk during critical neurodevelopmental windows.

Adolescence is marked by extensive neural pruning, synaptogenesis, and maturation of executive‑function circuits. The endocannabinoid system plays a central role in these processes, and exogenous cannabinoids can disrupt synaptic plasticity, dendritic architecture, glutamatergic signalling, CREB‑mediated gene expression, and NMDA‑dependent memory formation. As the paper notes, “cannabis can change adolescent gene expression and alter these key periods of neurodevelopment” . These alterations overlap with pathways implicated in opioid reinforcement and addiction.

Animal studies consistently show that adolescent THC or cannabinoid exposure enhances later heroin intake, increases conditioned place preference, induces morphine tolerance, and modifies striatal gene expression in ways that prime opioid sensitivity. Genetic variation (e.g., Penk, FosB expression) appears to moderate this priming effect, suggesting a subset of adolescents may be especially vulnerable.

Human population‑level studies mirror these concerns. Cannabis users are less likely to reduce opioid use over time, medical cannabis users show higher rates of prescription opioid misuse, and frequent cannabis use correlates with increased likelihood of meeting criteria for OUD. High‑potency cannabis may further amplify these risks. Additionally, cannabis‑related worsening of depression, suicidality, anxiety, and psychosis may indirectly increase opioid initiation among already at‑risk youth.

Overall, converging biological, developmental, genetic, and epidemiological evidence indicates that for some adolescents—particularly those with high‑risk genotypes or psychiatric vulnerability—cannabis use can meaningfully increase the likelihood of opioid initiation, escalation, and OUD.

Also see  Dalgarno Research Report Cannabis and the Gateway Drug Theory: Correlation or Causation – Where does the Evidence Point?